MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte ...
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human ...
The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading ...
SAB plans to be listed on NASDAQ following the closing of the transaction. The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of approximately $325 million (assuming ...
On Tuesday, SAB BIO (NASDAQ:SABS) released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary safety and pharmacodynamic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results